Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma

Primary pulmonary lymphoepithelioma‐like carcinoma (PLELC) is a rare and unique subtype of lung cancer. However, the prevalence of driver alterations, such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, and the response of tyrosine kinase inhibitor (TKIs) in PLELC has not been thoroughly investigated.

[1]  Yilong Wu,et al.  Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application. , 2019, Future oncology.

[2]  Huanming Yang,et al.  The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma , 2019, Nature Communications.

[3]  W. Guan,et al.  Clinical Features and Prognosis of Pulmonary Lymphoepithelioma-like Carcinoma: Summary of Eighty-five Cases. , 2019, Clinical lung cancer.

[4]  Yi-long Wu,et al.  Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. , 2018, Lung cancer.

[5]  Yi-long Wu,et al.  Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  T. Mok,et al.  Results of PROFILE 1029, a Phase III Comparison of First‐Line Crizotinib versus Chemotherapy in East Asian Patients with ALK‐Positive Advanced Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Jie Liu,et al.  P2.01-121 Genomic Profiling of Pulmonary Lymphoepithelioma-Like Carcinoma , 2018, Journal of Thoracic Oncology.

[8]  Xue-Ning Yang,et al.  P2.04-30 PD-1/PD-L1 Inhibition Might be an Option for the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma , 2018, Journal of Thoracic Oncology.

[9]  Yi-long Wu,et al.  Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer , 2018, Thoracic cancer.

[10]  S. Graziano,et al.  Pulmonary Lymphoepithelioma-like Carcinoma Disguised as Squamous Cell Carcinoma. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  F. Wang,et al.  Clinical Significance of Plasma Epstein‐Barr Virus DNA in Pulmonary Lymphoepithelioma‐like Carcinoma (LELC) Patients , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Ting-yan Lin,et al.  Primary lymphoepithelioma-like carcinoma of the lung: An unusual cancer and clinical outcomes of 14 patients. , 2017, Oncology letters.

[13]  Yi-long Wu,et al.  EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer , 2017, Oncoimmunology.

[14]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[15]  V. Rusch,et al.  Lung cancer — major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[16]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[17]  Yueh-Fu Fang,et al.  Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome. , 2017, Journal of thoracic disease.

[18]  G. Giaccone,et al.  Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. , 2016, Translational lung cancer research.

[19]  Yi-long Wu,et al.  EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now? , 2016, Trends in pharmacological sciences.

[20]  N. Ose,et al.  Pulmonary lymphoepithelioma‐like carcinoma with echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinase (EML4‐ALK) fusion gene , 2016, Respirology case reports.

[21]  Matteo Canale,et al.  Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors , 2016, Clinical Cancer Research.

[22]  W. Tam,et al.  Novel therapeutic targets on the horizon for lung cancer. , 2016, The Lancet. Oncology.

[23]  W. Liang,et al.  Surgical treatment for primary pulmonary lymphoepithelioma-like carcinoma. , 2016, Interactive cardiovascular and thoracic surgery.

[24]  Yu Zhang,et al.  Detection of rearrangement of anaplastic lymphoma kinase (ALK) and mutation of epidermal growth factor receptor (EGFR) in primary pulmonary lymphoepithelioma-like carcinoma. , 2015, Journal of thoracic disease.

[25]  J. Austin,et al.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  Y. Huang,et al.  PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival , 2015, Oncotarget.

[27]  L. Sequist,et al.  Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. , 2015, The Lancet. Oncology.

[28]  Yih-Leong Chang,et al.  PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. , 2015, Lung cancer.

[29]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[30]  Yi-long Wu,et al.  Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China , 2014, Lung Cancer.

[31]  Jian-Hua Fu,et al.  Lack of epidermal growth factor receptor gene mutations in exons 19 and 21 in primary lymphoepithelioma‐like carcinoma of the lung , 2014, Thoracic cancer.

[32]  T. Rong,et al.  Primary pulmonary lymphoepithelioma‐like carcinoma , 2012, Cancer.

[33]  R. Haba,et al.  Cytopathologic features and differential diagnostic considerations of primary lymphoepithelioma‐like carcinoma of the lung , 2012, Diagnostic cytopathology.

[34]  T. Mok,et al.  Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status , 2012, PloS one.

[35]  Yi-long Wu,et al.  Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[37]  Yih-Leong Chang,et al.  Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma‐like carcinomas , 2011, Cancer science.

[38]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[39]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[40]  T. Mok,et al.  Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[41]  M. Wong,et al.  Lymphoepithelioma‐like carcinoma of the lung , 2006, Respirology.

[42]  J. Minna,et al.  Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features , 2006, Clinical Cancer Research.

[43]  C. Cordon-Cardo,et al.  17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  W. Cho,et al.  Circulating Epstein-Barr virus DNA in serum of patients with lymphoepithelioma-like carcinoma of the lung: a potential surrogate marker for monitoring disease. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  T. Mok,et al.  Multimodality treatment of primary lymphoepithelioma‐like carcinoma of the lung , 1998, Cancer.

[46]  M. Cullen.  Evaluating new drugs in patients with chemosensitive tumours: ethical dilemmas in extensive small cell lung cancer , 1989 .

[47]  L. Bégin,et al.  Epstein‐barr virus related lymphoepithelioma‐like carcinoma of lung , 1987, Journal of surgical oncology.

[48]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[49]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[50]  M. Wood.  People's Republic of China. , 1979, The Alumni magazine.